Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

CDC7 inhibitor SGR-2921

An orally bioavailable small molecule inhibitor of cell division cycle 7-related protein kinase (CDC7), with potential antineoplastic activity. Upon oral administration, CDC7 inhibitor SGR-2921 targets, binds to and inhibits the activity of CDC7, which may result in an impaired response to replication stress, DNA damage, and the induction of tumor cell apoptosis. CDC7, a serine-threonine kinase overexpressed in a variety of tumor cell types, plays a key role in DNA replication and DNA damage response by binding to and phosphorylating serine (Ser)-40 and 53 of minichromosome maintenance complex component 2 (MCM2).

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	SGR 2921 SGR-2921 SGR2921

CDC7 inhibitor SGR-2921

Search NCI's Drug Dictionary